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Abstract
There is a significant demand in the molecular biophysics community for robust standard samples. They are required by 
researchers, instrument developers and pharmaceutical companies for instrumental quality control, methodological develop-
ment and in the design and validation of devices, diagnostics and instrumentation. To-date there has been no clear consensus 
on the need and type of standards that should be available and different research groups and instrument manufacturers use 
different standard systems which significantly hinders comparative analysis. One of the major objectives of the Association 
of Resources for Biophysical Research in Europe (ARBRE) is to establish a common set of standard samples that can be 
used throughout the biophysics community and instrument developers. A survey was circulated among ARBRE members 
to ascertain the requirements of laboratories when using standard systems and the results are documented in this article. In 
summary, the major requirements are protein samples which are cheap, relatively small, stable and have different binding 
strengths. We have developed a panel of sdAb’s or ‘nanobodies’ against hen-egg white lysozyme with different binding 
strengths and suitable stability characteristics. Here we show the results of the survey, the selection procedure, validation 
and final selection of a panel of nanobody interaction standards.
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Introduction
There is an unmet need within the molecular biophysics 
community for samples that can be used as standards across 
multiple diverse biophysical instruments. There are many 
different samples that are utilized as standards within indi-
vidual laboratories or provided by instrument manufacturers 
but there is a lack of continuity and consistency significantly 
impacting instrumental design, methodological development 
and data equivalence across multiple techniques. Standards 
are immensely important in the development of instrumenta-
tion and methodology and the availability of common stand-
ards will allow cross validation of techniques. Currently 
developers of biophysical devices use a variety of different 
standard samples for instrument validation and therefore 
comparability between instruments is unclear for both devel-
opers and customers. Likewise, research labs require stand-
ards for training, development and validating instrument 
performance. Benchmarking of instruments and methods is 
a critical way of ensuring instrument performance and high-
lighting common user errors. The development of common 
standard operating procedures (SOP’s) using well-studied 
standards would be beneficial for both biophysics resource 
labs and instrument developers alike.
ARBRE is a network of biophysics facilities and resource 
infrastructures that is ideally placed to spearhead the devel-
opment of common standard samples that can be imple-
mented in cross-instrumentation comparisons and bench-
marking studies and in the development of SOP’s for users 
across the biophysics communities. As part of an ARBRE 
supported initiative to develop standards, we disseminated 
a questionnaire to ascertain the most desirable qualities of 
standard samples prior to the development of a set of stand-
ard protein samples focusing on interaction analysis. The 
full results of the survey are presented in the supplemental 
material (Sup. 1 and 2). The standards we developed are sin-
gle domain antibody (sdAb) molecules with hen egg white 
lysozyme (HEWL) as the antigen or binding partner. Single 
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domain antibody fragments often referred to as nanobod-
ies, which is a trademark of Ablynx, are based on the vari-
able domain of heavy chain-only camelid antibodies (VHH) 
(Hassanzadeh-Ghassabeh et al. 2013; Jovcevska and Muyl-
dermans 2020; Muyldermans 2020; Revets et al. 2005; Vu 
et al. 1997). These small protein domains of between 12 
and 15 kDa are highly stable and easy to produce in large 
quantities, very soluble (Kim et al. 2014; Rouet et al. 2015; 
Salema and Fernandez 2013; Vu et al. 1997) and are also 
easy to be modified with functional groups, protein adjuncts 
and fluorescent probes (Al-Baradie 2020; Carrington et al. 
2019; Jovcevska and Muyldermans 2020; Mortensen et al. 
2020; Wang et al. 2019; Wu et al. 2018; Yu et al. 2020). The 
paratope of VHH sdAb’s consists of three variable comple-
mentarity determining regions (CDR) 1, 2 and 3 which con-
vey ligand specificity and binding strength. Typically, CDR3 
confers the greatest variability and is primarily responsible 
for ligand binding and specificity (McMahon et al. 2018; 
Moutel et al. 2016; Rouet et al. 2015; Zavrtanik et al. 2018). 
There are several reports on sdAb structure and stability 
(Kim et al. 2014; Muyldermans 2020; Zavrtanik et al. 2018), 
which show that the CDR3 loop is also primarily respon-
sible for the camelid VHH monomeric nature as compared 
to the human equivalent which has a propensity to dimer-
ize through the VH–VL interface, which is protected by the 
camelid CDR3 loop. Historically, nanobodies were gener-
ated in a similar way to full length antibodies through immu-
nization of llamas with the antigen of choice. However, there 
are now many synthetic libraries using ribosomal, phage or 
yeast display systems which have common frameworks but 
with variable CDR’s (Kajiwara et al. 2020; McMahon et al. 
2018; Moutel et al. 2016; Zimmermann et al. 2020).
The ability to generate multiple binding strength mol-
ecules against a single target is one of the primary reasons 
that sdAb molecules such as nanobodies are extremely 
attractive as molecules for standards. We have used both 
site-directed mutagenesis and phage display to generate a 
selection of nanobody molecules which are raised against 
HEWL and assessed their suitability for standard samples.
Experimental
Nanobody expression
The nanobody VHH sequence was engineered into pET-22B 
expression vector with a C-terminal 6-His tag. The vector 
was transformed into competent T7-Express E. coli cells 
(New England Biolabs) and selected on 100 µg/ml ampicil-
lin plates. One colony was selected for overnight growth 
in 5 ml LB broth supplemented with 100 µg/ml ampicillin 
shaking at 37 °C. The cells were pelleted by centrifugation 
at 2000 rpm for 5 min and resuspended in 5 ml of sterile LB. 
This suspension was used to inoculate 1 l of Magic Media™ 
(Thermofisher) divided between two 2 l baffled flasks and 
cells were incubated for 24 h at 28 °C on a rotary shaker 
set to 180 rpm. Cells were extracted by centrifugation at 
4500 rpm for 20 min at 4 °C with 250 ml cell suspension 
per 500 ml centrifuge tube and resuspended in 50 ml 50 mM 
phosphate-buffered saline (10 mM phosphate buffer with 
138 mM NaCl, 2.7 mM KCl) with 1% glycerol pH 7.0. Cells 
were then frozen at -80 °C until needed. Protein extraction: 
cells were thawed quickly then left on ice for 20 min before 
sonication in a Soniprep 150 tissue homogenizer (4 × 15 s) 
kept on ice. Cell debris was centrifuged at 14,000 rpm at 
4 °C for 10 min and the supernatant collected. The super-
natant was diluted 1:2 in 10 mM PBS pH 7.4 and injected 
onto a 5 ml Profinity IMAC column (BioRad) at 4 ml/min 
using a BioRad NGC FPLC. Protein was eluted in PBS sup-
plemented with 0.5 M ultrapure imidazole (Sigma) without 
a gradient and collected in deep-well 96-well plates. The 
elution peak was collected and further purified on a 10/300 
Superdex-75 column in PBS plus 0.005% P20 with a flow-
rate of 0.75 ml/min.
Surface plasmon resonance (SPR)
SPR was performed using a Biacore T200 (Cytiva life sci-
ence). Lysozyme was immobilized to a maximum loading 
level of 100 units using EDC/NHS coupling chemistry to 
link lysozyme primary amines to carboxyl groups on a CM5 
carboxymethyldextran sensor chip. Unused activated car-
boxyl groups were blocked using ethanolamine. A blank sen-
sor channel was activated and blocked in the same manner, 
but with no lysozyme attached. Lysozyme contains three 
surface lysine residues, none of which are within the nano-
body binding pocket. Kinetic titrations were performed in 
PBS containing 0.01% tween20 using the multi-cycle kinet-
ics wizard and a concentration series-dependent on the nano-
body but typically from between 100 and 200 nM. Regenera-
tion was perfomed by sequential 5 s injections of 100 mM 
Glycine pH 2.2 and 10 mM NaOH at 30 μl/min. Data are 
reported as an average of between 2 and 4 replicates and all 
fitting is performed using a Langmuir 1:1 binding model 
within the BiaEvaluation software.
Isothermal titration calorimetry (ITC)
ITC was performed using a Malvern PEAQ-ITC. Sam-
ples were purified from the gel-filtration column in phos-
phate buffered saline pH 7.4 (PBS) and frozen in 1 mg/
ml (~ 71  µM). For ITC, samples were defrosted on ice 
and diluted to a concentration of 20 µM for H04, H106A 
and Cab-Lys3 and the rest were diluted to 30 µM in PBS 
containing 0.005% tween 20. HEWL lysozyme powder 
(Roche > 95%) was made to 10 mg/ml (~ 690 µM) in PBS 
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Fig. 1  Results of survey questions. a Which areas would standards be most needed? b Which areas would you most likely use standards?
plus 0.005% tween 20 and further diluted to 200 µM for 
H04/H106A or 300 µM for the rest of the nanobodies. 
Lysozyme was equilibrated in the cell and nanobody was 
titrated using a preliminary injection of 0.2 µl, followed by 
18 succesive 2 µl injections with a reference power of 10, 
a stirring speed of 750 rpm and a spacing of 120 s between 
injections. Samples were run in triplicate and fitted using a 
single site model following subtraction.
Size exclusion calorimetry with multi‑angle light 
scattering
Samples (0.5 ml) were loaded onto a Superdex-75 10/300 
(GE) column running at a flow rate of 0.75 ml/min in PBS 
(pH 7.4). Samples eluting from the column passed through a 
Wyatt Helios 18-angle laser photometer with the 13th detec-
tor replaced with a Wyatt QELS detector for the simultane-
ous measurement of hydrodynamic radius. This was coupled 
to a Wyatt Optilab TrEX refractive index detector and the 
hydrodynamic radius, molecular mass moments and concen-
trations of the resulting peaks were analyzed using Astra V6.
Results and discussion
Survey results
A survey was distributed to the ARBRE mailing-list and 
was completed by 19 anonymized biophysics laboratories 
across Europe. The full survey results can be found in the 
supplemental information. Figure 1 shows the results of two 
questions: which areas of biophysics would you use standard 
samples, and which areas of biophysics would standards be 
most needed?
First, the questions determine what the standards would 
be used for, for example in testing their instruments for con-
formity or creating new methods. It also then checks which 
areas of biophysics the respondents think they need the 
standards the most, for example in interaction analysis or 
structural biophysics, and whether they prefer protein stand-
ards to DNA or small molecules. Of the biophysics labs 
that responded, the majority would like to use standards for 
testing their own equipment and comparing the results with 
other instrumentation. This is followed by a desire for cross 
lab comparisons of the same instrument or benchmarking. 
Given that most labs wish to check their own instruments 
conformity, benchmarking is presumably to test that their 
own instruments are performing to the best of their abili-
ties compared to other labs. Most labs prefer protein–pro-
tein interaction standards rather than protein–DNA or pro-
tein–small molecule as protein–protein interaction analysis 
is probably a more common practice. Interestingly there is a 
large number of respondents who would like to have hydro-
dynamic standards. There is a clear need for both interaction 
and hydrodynamic standards with the majority of respond-
ents indicating that they do not have in-house standards to 
use. The majority of labs required standards for interaction 
technologies such as surface plasmon resonance (SPR) and 
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isothermal titration calorimetry (ITC) although it could be 
that the respondents of the survey were more used to these 
technologies. Focusing on interaction techniques, Fig. 2 
shows the results for two practical questions: What would 
be the ideal molecular weight of standard samples, and what 
would be the ideal binding strengths?
Because molecular biophysics encompasses a wide vari-
ety of instrumentation, a single standard may not be appro-
priate. The results show that molecules with a molecular 
weight of between 10 and 30 kDa would be ideal. Binding 
strengths are also very important in the selection process for 
standard samples. Some instrumentation cannot investigate 
very tight binding, for example ITC cannot easily measure 
KD’s below 5 nM unless indirect approaches are used such as 
ligand displacement which would not be suited for a stand-
ard sample. Likewise some techniques cannot measure very 
weak interactions. The results to this question were very 
clearly showing that there is not one standard that will fit 
all purposes. There is a need for several standards with dif-
ferent binding strengths, although no respondents required 
standards that had a binding strength tighter than 1–10 nM, 
or weaker than 1 µM.
Rationale behind the development of nanobodies 
as standards
The criteria for gold-standard interaction standards there-
fore are; cheap, stable, 10–30 kDa with multiple binding 
strengths and well-characterized. To fulfil these criteria, we 
decided to investigate the applicability of nanobody mol-
ecules raised against lysozyme. Nanobodies typically have 
been shown to have high functional stability over a large pH 
range, good colloidal properties across different buffers and 
are easy to produce in high yields (Kim et al. 2014; Rouet 
et al. 2015; Salema and Fernandez 2013; Vincke et al. 2009). 
They have also been shown to be amenable to downstream 
engineering such as Fc fusion, GFP, double specificity, etc. 
(Marturano et al. 2020; Mortensen et al. 2020; Wu et al. 
2018; Yang and Shah 2020). These attributes therefore make 
nanobodies a good choice to investigate their potential as 
biophysics standards. The target we decided to use was 
hen egg white lysozyme (HEWL), and for the purposes of 
this article will be called lysozyme. Lysozyme is a small 
monomeric 14.5 kDa molecule that is extensively charac-
terized, stable, cheap and easy to purchase. Lysozyme has a 
Fig. 2  Survey questions relating to a what molecular weight standards should ideally be? And b how strong should the interaction be?
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deep cleft which is the native carbohydrate-binding region 
(Fig. 3) which makes it an ideal target for the CDR3 loop 
of nanobodies.
Nanobody standard development
The challenge for creating standards is to maintain a com-
mon structure, but to have different binding strengths. Most 
commercial nanobodies are very tight binders and one of the 
challenges for us was to create a selection of weaker binders. 
Mutation of the CDR3 loops is one way we created weaker 
binding molecules as well as to isolate weak binders from 
phage display. Several groups have previously made nano-
bodies to lysozyme (Dumoulin et al. 2002; Guardiola et al. 
2020; Muyldermans and Lauwereys 1999; Rouet et al. 2015; 
Vincke et al. 2009; Vu et al. 1997) but the focus of many of 
these was to create nanobodies with high binding strengths. 
Indeed, the selection process in phage display naturally 
favors selection of tighter binders. We decided to investigate 
two of these nanonodies, Cab-Lys3 (crystal structure 1XFP) 
developed by Muyldermans and Lauwereys (Muyldermans 
and Lauwereys 1999) and H04 developed in Daniel Christ’s 
group (Rouet et al. 2015) (Fig. 3). With the help of the crys-
tal structure to H04 (PDB code 4U3X), we first mutated 
residues Y99 to a phenylalanine, N105 and H106 to alanine 
which disrupts hydrogen bonds with residues R61, V109 
and E35, respectively, in the carbohydrate-binding cleft of 
lysozyme. We speculated that these mutations would signifi-
cantly decrease the binding strength.
The mutation Y99F and N105A which shares hydrogen 
bonds with Valine 109 and glutamic acid 57 completely 
abolished binding, therefore, these candidates were not taken 
forward. H106A, however, lowered the binding strength 
to ~ 250 nM by surface plasmon resonance (SPR) (Fig. 4). 
Based on the work by De Genst et al. (2002) we mutated 
residues within the CDR3 loop of Cab-Lys3, T101 to a ser-
ine and S105 to an asparagine. Cab-Lys3 has an extremely 
long CDR3 binding loop of 24 residues compared to H04 
which has 12 residues. Typically CDR3 loops range between 
9 and 18 residues (Moutel et al. 2016). This very long bind-
ing loop has an extra intraloop disulphide bridge which has 
been postulated to confer extra stability and increase binding 
affinity (Dumoulin et al. 2002; Kunz et al. 2018; Mendoza 
et al. 2020). The WT Cab-Lys3 in our hands has a binding 
strength of ~ 5 nM by SPR which is far too tight for many 
techniques. The two mutations T101S and S105N produced 
molecules with SPR affinities of 105 and 35 nM, respec-
tively (Fig. 4).
Using phage display, we generated several nanobody mol-
ecules that have lower binding strengths. Molecules were 
Fig. 3  a H04 bound to lysozyme highlighting CDR3 residues H106, 
Y99, N105 and b, Cab-Lys3 highlighting CDR3 residues S105 and 
T101. c Sequences of nanobodies with suitable characteristics for use 
as standard proteins. The red letters highlight the CDR3 loops and 
mutated amino acids are highlighted in blue
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Fig. 4  Chromatograms from a Superdex-75™ gel filtration column following = g purification and concentration series binding experiments using 
SPR (Biacore T200) fitted with a global 1:1 non-linear model and the affinity constant for each as determined by the model
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generated using the NaLi-H1 synthetic library (Moutel et al. 
2016) (Hybrigenics, Paris) which gave several molecules 
that were suitable, namely Phage-F07 and Phage-B09. These 
molecules have affinities based on SPR of 400 and 1300 nM, 
respectively (Fig. 4).
Suitability of the samples as standards
Standard samples need to be cheap to purchase, meaning 
they require an ease of manufacture. We assessed the puri-
fication levels of each of the clones (Table 1) expressed 
in pET-22B with a 6-His tag for purification. Purification 
was a simple two-step His-NTA followed by Superdex-75 
gel filtration in PBS (see methods). Expression yields 
ranged ~ three–fivefold, Cab-Lys3 constructs with the low-
est expression at ~ 10 mg/l, and H04/H106A expressing up 
to 50 mg/l. The phage display clones express at between 
20 and 30 mg/l depending on the clone. P-F07 and P-B09 
were ~ 30 mg/l. Whilst there is a significant difference, all 
these expression levels are suitable for standard sample 
production.
Samples also need to be monomeric and stable. Figure 4 
shows the elution positions of the nanobodies on a Super-
dex-75 gel filtration column following purification. Mono-
meric nanobodies elute at ~ 15 ml. However, with the H04 
and H106A variants we observed non-symmetrical peaks. 
This broader peak has a consistent mass across the differ-
ent eluting species (as shown using MALS (Fig. 5) which 
suggests that there is a proportion of the population that 
interacts with the column matrix.
Purification of all the nanobodies produces some dimers 
that are eluted from the His-trap column and are clearly 
visible by gel filtration. These dimers are more apparent 
with H04 and H106A and are non-reversible, which can 
be shown by gel filtration (Fig. 5a, inset) and by analytical 
ultracentrifugation (data not shown). Dimers are unreactive 
to lysozyme and for this reason, any dimers present in the 
samples cannot be seen using SPR and has no effect on the 
kinetics. Any dimers present in the sample does; however, 
have an effect on the n-number using ITC. Interestingly, 
we found that repeated freeze–thaw cycles to be the main 
contributing factor for a decrease in n-numbers indicating 
that freeze–thaw cycles contribute to nanobody aggregation. 
We also repeated ITC experiments with P-B09 6 months 
apart (proteins kept in sterile PBS) (Fig. 5b). There was little 
difference in the n-values and near identical results which 
suggests that the proteins are extremely stable when kept at 
4 °C. Taken together the results indicate that these nanobod-
ies represent a very stable framework which can be produced 
in large quantities to keep prospective costs to a minimum. 
They are amenable to multiple interaction technologies and 
we have produced molecules with several different affinities.
The H04 and phage‑display VHH sdAb’s exhibit 
different binding modes of action to the Cab‑Lys3 
mutants
All the molecules in this report exhibits near ideal 1:1 SPR 
traces (Fig. 4), but the Cab-Lys3 framework sdAbs have very 
different ITC characteristics as shown by ITC (Fig. 6). At 
20 °C all the molecules fit to a Langmuir 1:1 binding model 
using SPR, but at 20 °C Cab-Lys3, T101S and S105N have 
a weak endothermic response in contrast to H04, H106A, 
P-F07 and P-B09 which have strong exothermic binding 
responses. This is true at both 25° and 37 °C. This is very 
interesting as these molecules both bind within the HEWL 
Table 1  Expression levels and binding data for the nanobody standards






SPR KD (nM) SPR ka (M 
 s−1) ×  104
SPR kd 
 (s−1) ×  10–2
ITC KD (nM) ΔH (kcal/mol) ΔG (kcal/mol) − TΔS (kcal/mol)
H04 20 °C 50 19 ± 5 4.3 008 24 ± 3 − 17.6 − 10.4 7.2
H106A 20 °C 50 124 ± 68 45 5.6 296 ± 56 − 17.0 − 9.3 7.7
Cab-Lys3 20 °C 10 5 ± 4 4.1 0.09 27 ± 16 1.6 − 9.8 − 11.6
Cab-Lys3 37 °C 10 ND 5 ± 3 − 4.02 − 11.7 − 7.73
S105N 20 °C 10 35 ± 23 7.9 0.28 125 ± 66 2.6 − 9.3 − 11.6
S105N 37 °C 10 ND 73 ± 22 − 3.3 − 10.1 − 6.9
T101S 20 °C 10 135 ± 35 16 2.9 113 ± 39 3.0 − 9.3 − 12.4
T101S 37 °C 10 ND 105 ± 15 − 5.1 − 9.9 − 4.7
P-F07 20 °C 30 401 ± 56 2 8.2 685 ± 92 − 23.5 − 8.4 15.1
P-B09 20 °C 30 1300 ± 82 45 60 1430 ± 113 − 14.5 − 8.1 6.4
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carbohydrate-binding cleft. The major difference between 
the two molecules is the length of the CDR3 loop. Cab-Lys3 
has a very long 24-amino acid loop with an extra disulphide 
link between additional cysteines in CDR1 and CDR3. At 
room temperature the shorter CDR3 loop sdAb’s produce 
a large exothermic response with van’t Hoff enthalpy (ΔH) 
values in the range of − 14 to − 23 kcal/mol (Table 1), and 
this does not change significantly with increasing the tem-
perature (data not shown).
Conversely Cab-Lys3, T101S and S105N have small posi-
tive ΔH at room temperature and a large negative entropic 
effect upon binding to lysozyme which seems to suggest that 
the long binding loop requires significant reorganization to 
fit in to the binding cleft. The binding becomes more favora-
ble by increasing the temperature, decreasing the enthalpy 
and increasing the entropy. This seems to suggest that there 
is a enthalpy–entropy compensation mechanism ocuring 
(Chodera and Mobley 2013) which does not occur with the 
other nanobodies in this study. This system could be used as 
standard model for entropy–enthalpy compensation although 
this would need to be studied in greater detail.
Conclusions
The results of the survey into the need for standards in 
biophysics suggested the community requires standards 
for interaction analysis which are protein–protein based, 
between 10 and 30 kDa, stable, well-characterized and of 
several different affinities. We have developed a sdAb VHH 
Fig. 5  a Multi-angle light 
scattering of H04 eluting from 
a superdex-75 gel filtration 
column during the purification 
process. The non-symmetrical 
monomeric peak from the gel 
filtration column elutes at 15 ml 
and dimers elute earlier at 
12.5 ml. Monomers and dimers 
encountered during purification 
are non-reversible and can be 
separated (inset). b Isothermal 
titration calorimetry of P-B09 
6 months apart at 4 °C. Black 
trace is fresh P-B09, and the 
blue trace is 6 months later. 
Raw ITC (inset) and isotherm 
similarities highlights the 
stability and repeatability of the 
molecules
Fig. 6  ITC thermograms of the nanobody constructs. The signature 
plots of H04 and S105N are shown which highlights the significant 
difference in the mode of action between the two nanobodies
◂
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system to lysozyme which fulfils these requirements and has 
been used successfully in a benchmarking study for micro-
scale thermophoresis. We have shown that nanobodies can 
be extremely stable but they need to be carefully selected, 
and it is possible to manipulate them to alter the binding 
strength to create molecules with the desired binding affini-
ties. We have generated a panel of nanobodies that have 
affinities to lysozyme of between 5 and 1300 nM which are 
amenable to multiple techniques and we have also shown 
that some of these nanobodies have interesting thermody-
namics which increases the usability of these nanobodies 
for testing equipment. It is important to note that nanobod-
ies require careful selection to eliminate those molecules 
with undesirable characteristics such as aggregation and 
there is not one nanobody that is suitable for all techniques. 
For example, at room temperature the Cab-Lys3 molecules 
are not ideal for ITC. However, these nanobodies represent 
an exciting possibility to develop standard operating pro-
cedures that are adopted by labs and instrument developers 
alike and to standardize the way instrumental biophysics 
users are trained. They will hopefully allow manufacturers 
to use the same systems to develop their instruments and for 
users to benchmark their instruments and methodological 
developments.
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